Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Lymphocytic Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Hematopoietic and Lymphoid Cell Neoplasm
Lymphocytic Neoplasm

Cancer Family

Lymphocytic Neoplasm

CI-CAN-00000223Explore in graph →

HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items

NCIt: C7065

Overview
Statistics
Survival
Genomics38
Variants & evidence345
Drugs51
Trials12948
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (351)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 276–300 of 351 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review.
· J Pediatr Hematol Oncol · 2021 · PMID 32068648 · validated civic_curation pubmed
The t(1;9)(p34;q34) fusing ABL1 with SFPQ, a pre-mRNA processing gene, is recurrent in acute lymphoblastic leukemias.
· Leuk Res · 2011 · PMID 21388681 · validated civic_curation pubmed
SFPQ-ABL1-positive B-cell precursor acute lymphoblastic leukemias.
· Genes Chromosomes Cancer · 2020 · PMID 32306475 · validated civic_curation pubmed
t(1;9)(p34;q34)/SFPQ-ABL1 Fusion in a Patient with Ph-Like Common B-Cell Acute Lymphoblastic Leukemia.
· Acta Haematol · 2017 · PMID 27894117 · validated civic_curation pubmed
A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34).
· Haematologica · 2009 · PMID 19794096 · validated civic_curation pubmed
RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations.
· Int J Hematol · 2011 · PMID 21863287 · validated civic_curation pubmed
Acute lymphoblastic leukemia associated with RCSD1-ABL1 novel fusion gene has a distinct gene expression profile from BCR-ABL1 fusion.
· Leukemia · 2013 · PMID 23168614

Showing 276–300 of 351 publications

← Previous
1
…
11
12
13
14
15
Next →

· validated civic_curation

Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with RCSD1-ABL1-positive acute lymphoblastic leukemia.

· Haematologica · 2017 · PMID 28057740 · validated civic_curation pubmed

Cryptic ETV6-ABL1 Fusion and MLL2 Truncation Revealed by Integrative Clinical Sequencing in Multiply Relapsed Acute Lymphoblastic Leukemia.

· J Pediatr Hematol Oncol · 2019 · PMID 30028819 · validated civic_curation pubmed

Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia.

· Blood Cancer J · 2015 · PMID 25768406 · validated civic_curation pubmed

Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements.

· Blood · 2019 · PMID 31434701 · validated civic_curation pubmed

Rapid Molecular Response to Dasatinib in a Pediatric Relapsed Acute Lymphoblastic Leukemia With NCOR1-LYN Fusion.

· Front Oncol · 2020 · PMID 32266142 · validated civic_curation pubmed

Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma.

· Genes (Basel) · 2020 · PMID 32668764 · validated civic_curation pubmed

Unusual PDGFRB fusion reveals novel mechanism of kinase activation in Ph-like B-ALL.

· Leukemia · 2023 · PMID 36810896 · validated civic_curation pubmed

Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response.

· Eur J Haematol · 2014 · PMID 24330038 · validated civic_curation pubmed

Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion.

· Mol Genet Genomic Med · 2015 · PMID 25802883 · validated civic_curation pubmed

Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia.

· Pediatr Blood Cancer · 2017 · PMID 27860260 · validated civic_curation pubmed

NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors.

· Haematologica · 2016 · PMID 26681761 · validated civic_curation pubmed

Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript.

· Eur J Haematol · 2014 · PMID 24215620 · validated civic_curation pubmed

Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia.

· Br J Haematol · 2011 · PMID 21391972 · validated civic_curation pubmed

Identification of novel kinase fusion transcripts in paediatric B cell precursor acute lymphoblastic leukaemia with IKZF1 deletion.

· Br J Haematol · 2015 · PMID 26404892 · validated civic_curation pubmed

Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.

· Blood · 2020 · PMID 32232486 · validated civic_curation pubmed

Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma.

· Br J Haematol · 2019 · PMID 31234236 · validated civic_curation pubmed

The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1.

· Genes Chromosomes Cancer · 2008 · PMID 18205209 · validated civic_curation pubmed

A new partner gene fused to ABL1 in a t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia.

· Leukemia · 2007 · PMID 17541395 · validated civic_curation pubmed